Gapping up
In reaction to earnings/guidance:
- UPST +22.1%, FUBO +21.1%, SD +10.4%, BIGC +5.4%, WEN +5.3%, U +5%, CHK +5% (also initiates dividend), DEO +3.8%, NEWT +3.7% (also increases dividend), CNR +3.6%, NARI +3%, SNDX +2.4%, HLI +2.1%, TM +2.1%, OPEN +2%, DT +1.9%, OLO +1.8%, JAMF +1.4% (also to acquire Wandera for $400 mln), EA +1.4%
Other news:
- EYES +24.4% (announces two-year results of its orion study)
- WISA +13.6% (certified Onkyo sound sphere audio system launches in Japan)
- CVI +11.5% (announces special dividend)
- SIEN +9.2% (to sell miraDry business to 1315 Capital)
- BNR +5.3% (to be added to MSCI China Index, effective after the U.S. market close on May 27)
- ABST +3.9% (to acquire NetMotion for $340 mln in cash)
- TDUP +3.5% (to power resale for Very Bradley through Resale-as-a-Service),
- INVZ +3.4% (selected by a leading Tier-1 automotive supplier as the LiDAR provider for its multi-year autonomous shuttle program)
- PROG +3.2% (announces preliminary results, subject to final audited study reports by its contract research organization, from two key studies for the Company's Targeted Therapeutics program)
- CENH +3.1% (to combine with Arqit Limited, a leader in quantum encryption technology)
- SLM +2.4% (ValueAct (Bradley E. Singer) lowers active stake to 7.2% (prior ~10%))
- CAE +2.2% (to accelerate the design and development of Jaunt Air Mobility's eVTOL aircraft by leveraging the latest simulation technologies)
- DFNS +2% (IronNet named manufacturer on ITES-SW2 contract),
- IFRX +2% (announces top-line results from Phase II IXPLORE study)
- ANAT +1.9% (issues response to recent media reports)
- FULC +1.2% (announces that the U.S. Food and Drug Administration has granted Fast Track designation to losmapimod for the potential treatment of facioscapulohumeral muscular dystrophy)
- SRRK +1.1% (announces publication of Phase 1 trial data evaluating apitemograb)
- CLLS +1.1% (announces partnership with SNY for alemtuzumab)
- ADS +1% (to spin off its LoyaltyOne segment, comprising its Canadian AIR MILES Reward Program and BrandLoyalty business)
Analyst comments:
- RXT +2.4% (upgraded to Strong Buy from Outperform at Raymond James)
- HBI +1.9% (upgraded to Equal Weight from Underweight at Wells Fargo)
- NLOK +1.5% (upgraded to Buy from Underperform at BofA Securities)